Dynamics of Long-term Colonization of Respiratory Tract by Haemophilus Influenzae in Cystic Fibrosis Patients Shows a Marked Increase in Hypermutable Strains
Overview
Affiliations
The persistence and variability of 188 Haemophilus influenzae isolates in respiratory tract of 30 cystic fibrosis (CF) patients over the course of 7 years was studied. Antibiotic susceptibility testing, DNA fingerprinting, and analysis of outer membrane protein profiles were performed on all isolates. A total of 115 distinct pulsed-field gel electrophoresis profiles were identified. Ninety percent of patients were cocolonized with two or more clones over the studied period. A third of the patients were cross-colonized with one or two H. influenzae strains; 11% of the clones persisted for 3 or more months. Biotype, outer membrane protein profiles, and resistance profiles showed variation along the studied period, even in persisting clones. Four isolates (2.1%) recovered from 3 patients were type f capsulate, with three of them belonging to the same clone. beta-Lactamase production was detected in 23.9% of isolates while 7% of the beta-lactamase-negative isolates presented diminished susceptibility to ampicillin (beta-lactamase-negative ampicillin resistance phenotype). Remarkably, 21.3% of the H. influenzae isolates presented decreased susceptibility to ciprofloxacin, which was mainly observed in persisting clones. Of the H. influenzae isolates from CF patients, 18 (14.5%) were found to be hypermutable in comparison with 1 (1.4%) from non-CF patients (P < 0.0001). Ten patients (33.3%) were colonized by hypermutable strains over the study period. A multiresistance phenotype and long-term clonal persistence were significantly associated in some cases for up to 7 years. These results suggest that H. influenzae bronchial colonization in CF patients is a dynamic process, but better-adapted clones can persist for long periods of time.
Weyant R, Waddell B, Acosta N, Izydorczyk C, Conly J, Church D BMC Infect Dis. 2024; 24(1):1209.
PMID: 39465381 PMC: 11520053. DOI: 10.1186/s12879-024-10050-7.
Beyond antibiotics: CRISPR/Cas9 triumph over biofilm-associated antibiotic resistance infections.
Zuberi A, Ahmad N, Ahmad H, Saeed M, Ahmad I Front Cell Infect Microbiol. 2024; 14:1408569.
PMID: 39035353 PMC: 11257871. DOI: 10.3389/fcimb.2024.1408569.
Insights into the Adolescent Cystic Fibrosis Airway Microbiome Using Shotgun Metagenomics.
McDermott G, Walsh A, Crispie F, Frost S, Greally P, Cotter P Int J Mol Sci. 2024; 25(7).
PMID: 38612702 PMC: 11011389. DOI: 10.3390/ijms25073893.
Izydorczyk C, Waddell B, Weyant R, Surette M, Somayaji R, Rabin H Sci Rep. 2022; 12(1):15765.
PMID: 36131075 PMC: 9492733. DOI: 10.1038/s41598-022-19240-2.
Adaptation and Evolution of Pathogens in the Cystic Fibrosis Lung.
Planet P J Pediatric Infect Dis Soc. 2022; 11(Supplement_2):S23-S31.
PMID: 36069898 PMC: 9451014. DOI: 10.1093/jpids/piac073.